Sector News

Australia’s CSL buys Novartis flu vaccine unit for $275 mln

October 27, 2014
Life sciences
(Reuters) – Australia’s CSL Ltd , the world’s largest blood products company, said on Monday it had agreed to buy Novartis AG’s global influenza vaccine business for $275 million, part of the Swiss drugmaker’s drive to focus on its best assets.
 
The sale of the flu business will conclude Novartis’ overhaul of its units which it had flagged in April, aimed at strengthening its cancer business and exiting underperforming operations.
 
Novartis said in April GlaxoSmithKline was buying its vaccines business, excluding flu, for $5.25 billion plus potential milestone payments of up to $1.8 billion and royalties.
 
The sale of its flu business to CSL will trigger an exceptional pretax impairment charge of approximately $1.1 billion, as the selling price is below the book value of the assets, Novartis said in a statement on Monday.
 
The charge will be excluded from the Swiss drugmaker’s core results and a one-time operating income gain expected from the deal with GSK will compensate for the charge, it said.
 
Combining the Novartis unit with CSL subsidiary bioCSL would create the No.2 player in the $4 billion global influenza vaccine industry, CSL said in a statement to the Australian stock exchange.
 
CSL, which said it would fund the deal with surplus cash, estimated integration costs at $100 million, while synergy benefits were seen at $75 million a year by 2020.
 
The deal is expected to close in the second half of 2015, pending regulatory approval, Novartis said. (Reporting by Lincoln Feast in Sydney and Alice Baghdjian in Zurich; Editing by Robin Pomeroy and David Holmes)

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach